Bragagni Marco, Carta Fabrizio, Osman Sameh M, AlOthman Zeid, Supuran Claudiu T
a Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche e Nutraceutiche , Università degli Studi di Firenze , Sesto Fiorentino , Florence Italy.
b Department of Chemistry, College of Science , King Saud University , Riyadh , Saudi Arabia.
J Enzyme Inhib Med Chem. 2017 Dec;32(1):701-706. doi: 10.1080/14756366.2017.1302441.
Acridine orange (AO) a fluorescent cationic dye used for the management of human musculoskeletal sarcomas, due to its strong tumoricidal action and accumulation in the acidic environment typical of hypoxic tumors, was used for the preparation of a primary sulfonamide derivative. The rationale behind the drug design is the fact that hypoxic, acidic tumors overexpress carbonic anhydrase (CA, EC 4.2.1.1) isoforms, such as CA IX, which is involved in pH regulation, proliferation, cell migration and invasion, and this enzyme is strongly inhibited by primary sulfonamides. The AO-sulfonamide derivative was indeed a potent, low nanomolar CA IX inhibitor whereas its inhibition of the cytosolic isoforms CA I and II was in the micromolar range. A second transmembrane, tumor-associated isoform, CA XII, was also effectively inhibited by the AO-sulfonamide derivative, making this compound an interesting theranostic agent for the management of hypoxic tumors.
吖啶橙(AO)是一种用于治疗人类肌肉骨骼肉瘤的荧光阳离子染料,由于其强大的杀肿瘤作用以及在缺氧肿瘤典型的酸性环境中的积聚,被用于制备一种初级磺酰胺衍生物。药物设计背后的基本原理是,缺氧的酸性肿瘤会过度表达碳酸酐酶(CA,EC 4.2.1.1)同工型,如参与pH调节、增殖、细胞迁移和侵袭的CA IX,而这种酶会被初级磺酰胺强烈抑制。AO-磺酰胺衍生物确实是一种强效的低纳摩尔CA IX抑制剂,而其对胞质同工型CA I和CA II的抑制作用在微摩尔范围内。第二种跨膜肿瘤相关同工型CA XII也被AO-磺酰胺衍生物有效抑制,这使得该化合物成为一种用于治疗缺氧肿瘤的有趣的诊疗剂。